Urovant Sciences, Inc.
5151 California Avenue
About Urovant Sciences, Inc.
Urovant Sciences is a clinical-stage global biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant is a fast moving company with an entrepreneurial focus on improving the way and working on new therapies for patients affected by urologic conditions and their health care providers to treat and manage urologic diseases.
Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment recognizes results, strategic decision-making and collaboration, giving team members opportunities to grow in this fast-moving company.
Urovant's lead product candidate, vibegron, is a β3-adrenergic agonist being developed for an oral, once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Urovant's second investigational product candidate, hMaxi-K, is a novel gene therapy for patients with overactive bladder (OAB) who have failed oral pharmacologic therapy. Urovant holds world-wide rights to this novel gene therapy.
Overactive bladder is a clinical condition characterized by the sudden urge to urinate, with or without accidental urinary leakage, and usually with increased urinary frequency. . In the United States, more than 30 million people over the age of 40 suffer from the bothersome symptoms of OAB1, which can lead to depression and anxiety and have a negative impact on quality of life.2
1. Coyne, et al., EpiLUTS 2007
2. Kinsey D, et al., J Health Psychol. 2016
Stock Symbol: UROV
Stock Exchange: NASDAQ
25 articles with Urovant Sciences, Inc.
The event will feature presentations by clinical experts in the field of urology, Dr. Roger R. Dmochowski, Vanderbilt University, and Dr. Steven Kaplan, Icahn School of Medicine at Mount Sinai.
Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018.
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced chief executive officer Keith A. Katkin is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 a.m. PT in San Francisco.
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to participate in the Piper Jaffray Healthcare Conference on Tuesday, November 27
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
Urovant Sciences Ltd. today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target
The study demonstrated once-daily vibegron was well-tolerated and improved OAB symptoms
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
Kyorin Receives Approval from Japan's Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Kyorin secures first commercial approval for vibegron
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
There are no currently available FDA-approved gene therapy treatments for overactive bladder
Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
Urovant Sciences announced the appointments of Sef Kurstjens, M.D., Ph.D. and Pierre Legault to its board of directors.
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.